JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS mutant tumor pre-clinical models

被引：0
|
作者：
Hauptschein, Robert [1 ]
Woodcock, Simon [2 ]
Belfield, Andrew [2 ]
Mason, Helen [2 ]
Keppel, Dorottya [2 ]
Markova, Svetlana [1 ]
Kim, Kyuri [1 ]
Roller, Shane [1 ]
Phillips, Caroline [2 ]
Jones, Clifford D. [2 ]
Humphreys, Robin C. [1 ]
机构：
[1] Jazz Pharmaceut, Palo Alto, CA USA
[2] Redx Pharma, Manchester, Lancs, England
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2677
引用
收藏
页数：1
相关论文
共 50 条
  • [21] AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia
    Keeton, Erika
    Palakurthi, Sangeetha
    Alimzhanov, Marat
    Grondine, Michael
    Chen, Yuching
    Brown, Jeffrey
    McEachern, Kristen
    Cao, Yichen
    Chinnappan, Dharmaraj
    Shen, Minhui
    Dakin, Les
    Zheng, Xiao
    Lamb, Michelle
    Wu, Allan
    Chen, Huawei
    Lyne, Paul
    Huszar, Dennis
    BLOOD, 2011, 118 (21) : 669 - 670
  • [22] AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia
    Keeton, Erika K.
    McEachern, Kristen
    Dillman, Keith S.
    Palakurthi, Sangeetha
    Cao, Yichen
    Grondine, Michael R.
    Kaur, Surinder
    Wang, Suping
    Chen, Yuching
    Wu, Allan
    Shen, Minhui
    Gibbons, Francis D.
    Lamb, Michelle L.
    Zheng, Xiaolan
    Stone, Richard M.
    DeAngelo, Daniel J.
    Platanias, Leonidas C.
    Dakin, Les A.
    Chen, Huawei
    Lyne, Paul D.
    Huszar, Dennis
    BLOOD, 2014, 123 (06) : 905 - 913
  • [23] Role of neurotrophin-trk interactions in oncology: The anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models
    Ruggeri, BA
    Miknyoczki, SJ
    Singh, J
    Hudkins, RL
    CURRENT MEDICINAL CHEMISTRY, 1999, 6 (09) : 845 - 857
  • [24] Targeting the Raf/MEK/ERK signaling pathway by the novel MEK inhibitor PD0325901:: Molecular and functional effects in pre-clinical leukemia models
    Ricciardi, M. R.
    Milella, M.
    Scerpa, M. C.
    Gregorj, C.
    De Cave, F.
    Abrams, S.
    Steelman, L.
    Chiaretti, S.
    Konopleva, M.
    Petrucci, M. T.
    Cognetti, F.
    Foa, R.
    Andreeff, M.
    McCubrey, J.
    Tafuri, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 278 - 279
  • [25] GSK1120212 is a novel Mek inhibitor demonstrating sustained inhibition of ERK phosphorylation and selective inhibition of B-Raf and RAS mutant cells in preclinical models
    Gilmartin, A. G.
    Kusnierz, A. M.
    Sutton, D.
    Moss, K. G.
    Thompson, C. S.
    Weber, B. L.
    Copeland, R. A.
    Jackson, J. R.
    Laquerre, S. G.
    EJC SUPPLEMENTS, 2008, 6 (12): : 178 - 178
  • [26] The novel, irreversible proteasome inhibitor PR-171 demonstrates potent anti-tumor activity in pre-clinical models of multiple myeloma, and overcomes bortezomib resistance.
    Kuhn, Deborah J.
    Chen, Qing
    Voorhees, Peter M.
    Strader, John S.
    Shenk, Kevin D.
    Sun, Congcong M.
    Demo, Susan D.
    Bennett, Mark K.
    van Leeuwen, Fred W.
    Orlowski, Robert Z.
    BLOOD, 2006, 108 (11) : 987A - 988A
  • [27] RP-3500: A novel, potent and selective ATR inhibitor that is effective in pre-clinical models as a monotherapy and in combination with PARP inhibitors
    Roulston, Anne
    Zimmerman, Michal
    Papp, Robert
    Skeldon, Alex
    Pellerin, Charles
    Dumas-Berube, Emilie
    Dumais, Valerie
    Dorich, Stephane
    Fournier, Sara
    Li, Li
    Leclaire, Marie-Eve
    Yin, Shou Yun
    Chefson, Amandine
    Alam, Hunain
    Yang, William
    Fugere-Desjardins, Chloe
    Hammond, Sabrina
    Skorey, Kathryn
    Mulani, Amina
    Rimkunas, Victoria
    Veloso, Artur
    Hamel, Martine
    Stocco, Rino
    Mamane, Yael
    Li, Zuomei
    Young, Jordan
    Zinda, Mike
    Black, Cameron
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [28] Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma
    Spira, Alexander
    Gambardella, Valentina
    Kato, Shumei
    Perez, Cesar Batista
    Mckean, Meredith
    Cao, Maria Gonzalez
    Kim, Richard
    Chen, Chris T.
    Italiano, Antoine
    Cassier, Philippe
    Mehnert, Janice
    Chmielowski, Bartosz
    Lee, Gerri
    Severson, Paul
    Unger, Caro
    Guan, Xiaowei
    Williams, Richard
    Long, Georgina
    CANCER RESEARCH, 2023, 83 (08)
  • [29] Pan-RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4 and 6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
    Chen, Shih-Hsun
    Zhang, Youyan
    Van Horn, Robert D.
    Yin, Tinggui
    Huber, Lysiane
    Burke, Teresa F.
    Gong, Xueqian
    Wu, Wenjuan
    Bhagwat, Shripad
    Buchanan, Sean
    Beckmann, Richard P.
    Tiu, Ramon V.
    Peng, Sheng-Bin
    CANCER RESEARCH, 2016, 76
  • [30] Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma
    Sriskandarajah, Priya
    Boyd, Kevin
    Xu, Wen
    Candilejo, Irene Moreno
    Ellis, Sidra
    Price, Amy
    Sherborne, Amy L.
    Croft, James
    Shah, Vallari
    Dawes, Joanna
    Parmar, Mona
    Turner, Alison
    Hall, Emma
    Tunariu, Nina
    Lopez, Juanita S.
    de Bono, Johann S.
    Banerji, Udai
    Kaiser, Martin
    BLOOD, 2018, 132
12345